Bendamustine, Bortezomib and Dexamethasone (BBD) As First-Line Treatment of Patients (Pts) with Multiple Myeloma (MM) Who Are Not Candidates for High Dose Chemotherapy
Jesús G. Berdeja(Tennessee Oncology), Ian W. Flinn(Tennessee Oncology), Todd M. Bauer(Tennessee Oncology), James Essell(Oncology Hematology Care), Péter Ács(Georgetown University), Luis Chu(Sarah Cannon), Ralph V. Boccia(Center for Cancer and Blood Disorders), Edward Arrowsmith(Center for Cancer and Blood Disorders)
Cited by 2
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k